Johnson and Johnson (J&J) subsidiary, Janssen Biotech, has licensed global rights to the preclinical Crohn’s disease (CD) drug candidate, PTG-200, from Protagonist Therapeutics in a deal potentially worth nearly US$1 B. PTG-200 is an interleukin-23 receptor antagonist that is delivered orally, offering a more convenient delivery method for patients with moderate-to-severe CD that are currently treated with biologics, such as Humira® (adalimumab) and Remicade® (infliximab).